Having trouble accessing articles? Reset your cache.

Treanda bendamustine regulatory update

SymBio and partner Eisai said Japan's Ministry of Health, Labor and Welfare (MHLW) lifted a postmarketing surveillance requirement for Treakisym bendamustine, which is approved to treat refractory/relapsed low-grade non-Hodgkin's lymphoma

Read the full 306 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE